Affiliation:
1. the General Hospital, Ningxia Medical University
2. Ningxia Medical University
3. The General Hospital of Ningxia Medical University
Abstract
Abstract
Castleman disease(CD), also known as giant lymphadenopathy or angiofollicular lymphadenopathy, was firstly reported by Castleman in 1954[1]. CD is a rare chronic lymphoproliferative disease, and its etiology and pathogenesis is still not completely clear. Clinically, according to the distribution of swollen lymph nodes, CD is divided into Unicentric CD (UCD) and multicentric CD (MCD). The main manifestations of UCD are single-site lymph node enlargement, lack of specific clinical manifestations and abnormal laboratory indicators. MCD mostly presents as diffuse lymphadenopathy, which is a rare polyclonal B lymphoproliferative disorder that straddles the intersections of hematology, oncology, rheumatology, and virology[2]. CD that presents with diffuse parenchymal lung disease is extremely rare. Here, we report a 48-year-old woman diagnosed with CD, which presents with diffuse nodules in both lungs.
Publisher
Research Square Platform LLC
Reference30 articles.
1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by, Cabot RC. N Engl J Med. 1954;251(10):396–400.Hospital: Case No. 40231. N Engl J Med. 1954. 250(23): 1001–1005.
2. Internationvidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease Blood;Rhee FV,2018
3. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element;An J;Blood,2002
4. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo;Keller SA;Blood,2006
5. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease;Polizzotto MN;Blood,2013